Feature | March 31, 2014

Radiotherapy After Mastectomy Benefits Women With Breast Cancer in 1-3 Lymph Nodes

Radiotherapy Mastectomy Women Breast Cancer Lymph Nodes

March 31, 2014 — Women whose breast cancer has spread to just a few lymph nodes under their arm are less likely to have their disease recur or to die from it if they have radiotherapy after mastectomy, according to new research to be presented at the European Breast Cancer Conference (EBCC-9) and published in The Lancet. [1]

Dr. Paul McGale said, until now, there has been uncertainty over whether women with early breast cancer that has spread to just one, two or three lymph nodes under the arm gain any benefit from radiotherapy after surgery. However, his findings show that radiotherapy improves their chances of remaining disease-free and reduces their risk of dying from breast cancer.

"Another result from our study is that the proportional benefits of radiotherapy were similar in women regardless of whether or not they had also received chemotherapy or hormonal therapy. This is important because most women today receive these therapies. Our results suggest that women being treated today are likely also to benefit from radiotherapy if they have any positive lymph nodes," he told an EBCC-9 news briefing for journalists.

McGale, Ph.D., a senior statistician in the Early Breast Cancer Trialists' Collaborative Group at the Clinical Trial Service Unit (Oxford, U.K.), analyzed results from 3,786 women in 14 randomized trials starting between 1964-1982, who had been given mastectomies along with the surgical removal of lymph nodes under the arm (axillary dissection) and who were then randomized to receive either radiotherapy to the chest wall and surrounding regions or to no radiotherapy. The women fell into three categories: those with no cancer in the lymph nodes, those with cancer in one, two or three lymph nodes, and those with cancer in four or more lymph nodes. The women were followed up for an average of just over 11 years, and data on the number of recurrences and deaths were available up to 2009.

"In 700 women in whom the pathologists could find no sign that the nodes were affected, radiotherapy did not reduce the risk of recurrence or of dying from breast cancer," said McGale. "However, in the 1,314 women who had between one and three positive nodes, radiotherapy reduced the recurrence rate by nearly a third (32%) and the breast cancer death rate by a fifth (20%). Giving radiotherapy to these women led to nearly 12 fewer recurrences of breast cancer per 100 women after ten years, and eight fewer deaths per 100 women after 20 years."

He found that the percentage reductions in the recurrence and death rates in the 405 women who had only one positive node were similar to those for the women who had two or three positive nodes.

For the 1,772 women with four or more positive nodes, radiotherapy also reduced the recurrence rate (by 21%) and the breast cancer death rate (by 13%). Here, radiotherapy for these women led to nine fewer recurrences of breast cancer after ten years and nine fewer deaths after 20 years per 100 women.

"It is already accepted that women with four or more positive nodes benefit from radiotherapy after mastectomy, and these findings confirm this benefit," he said. "However, it is for women with between one and three positive nodes where the previous evidence has been unclear."

The benefit occurred regardless of whether or not the women were in trials where chemotherapy or hormonal therapy was given to all women. Sixty-five percent of women with one, two or three positive nodes received chemotherapy, and a further 21% with hormone sensitive tumors received hormonal therapy.

Speaking before the conference, Dr. Carolyn Taylor (FRCR), a clinical oncologist in the Early Breast Cancer Trialists' Collaborative Group, said, "In the past, most women with many positive lymph nodes were given chemotherapy, but usually those with few positive nodes were not. In recent years, larger numbers of women with just a few positive lymph nodes have received chemotherapy, and the types of chemotherapy have changed. Also the vast majority of women with hormone-sensitive tumors are now given hormonal therapy. We will have to wait for results from new trials to observe directly the long-term effects of modern radiotherapy in women who are given modern chemotherapy and hormonal therapy. However, it is likely that the percentage reductions in disease recurrence and breast cancer mortality from today's radiotherapy will be at least as big as the benefits seen here."

"Since the time when the women in these trials were randomized there have been advances in radiotherapy and also in breast screening, surgery, lymph node staging, and systemic therapy," McGale concluded. "So the absolute benefits from post-mastectomy radiotherapy today may be smaller than those we have reported here. But the proportional benefits from radiotherapy are likely to be at least as big."

To investigate this and follow up on their findings, McGale, Taylor and their colleagues are inviting investigators of more recent trials comparing different radiotherapy regimens to contribute data to the Early Breast Cancer Trialists' Group.

Prof. David Cameron, from the University of Edinburgh (Edinburgh, United Kingdom), who is a member of the EBCC-9 executive scientific committee, commented: "These data highlight the power of combining information from individual patients recruited into a number of different clinical trials. The benefit of radiotherapy in women who needed a mastectomy for node positive breast cancer is now becoming clear; more data will emerge in a few years from the U.K.-led SUPREMO trial which prospectively addresses this question for the exact same group of women that are the subject of this study."

The 3786 women were part of a larger group of 8,135 women in 22 randomized trials starting before 2000. During the follow-up period, 5,424 (67%) were known to have died, and the extent of surgery was know for all but 183 (2%) of the women.

Abstract no: O-202, "Effect of radiotherapy after mastectomy and axillary dissection on recurrence and breast cancer mortality: meta-analysis of individual patient data from randomised trials." March 20. "Radiotherapy – no longer the same for all" session, Lomond Auditorium.

References:

[1] "Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials", by EBCTCG (Early Breast Cancer Trialists' Collaborative Group). Published online in The Lancet, March 19, 2014, http://dx.doi.org/10.1016/S0140-6736(14)60488-8.

Related Content

DOSIsoft Receives FDA 510(k) Clearance for Planet Onco Dose Software
Technology | Information Technology | June 20, 2019
DOSIsoft announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Planet...
Bay Labs Announces New Echocardiography Guidance Software Data at ASE 2019 Scientific Sessions
News | Cardiovascular Ultrasound | June 20, 2019
Bay Labs announced that new data on the company’s first-of-its-kind deep learning investigational guidance software...
LVivo EF Comparable to MRI, Contrast Echo in Assessing Ejection Fraction
News | Cardiovascular Ultrasound | June 19, 2019
DiA Imaging Analysis announced the presentation of two studies assessing the performance and accuracy of the company's...
New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
Warm Springs Health & Wellness Center Implements Digisonics Solution for OB Ultrasound
News | Ultrasound Women's Health | June 17, 2019
Warm Springs Health & Wellness Center in Warm Springs, Ore., has selected the Digisonics OB PACS (picture archiving...
Fujifilm Announces Nationwide Breast Health Campaign With Mobile Mammography Coach

At the center of the campaign, Fujifilm will be traveling around the U.S. with its "Aspire to Be Fearless" mobile mammography coach to provide educational opportunities for clinicians, raise awareness about the importance of screening and will be providing mammograms to the underserved population in key locations.

News | Mammography | June 14, 2019
Fujifilm Medical Systems U.S.A. Inc. announced a nationwide awareness campaign titled ‘Aspire to Be Fearless’ focused...
University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA
News | Proton Therapy | June 14, 2019
IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and...
Ikonopedia Showcases Risk Assessment and Resolution Manager Tools at SIIM and AHRA
News | Mammography Reporting Software | June 13, 2019
Ikonopedia will showcase its suite of structured breast reporting and Mammography Quality Standards Act (MQSA)...
iCAD Introduces ProFound AI for 2D Mammography in Europe
News | Artificial Intelligence | June 13, 2019
iCAD Inc. announced the launch of ProFound AI for 2D Mammography in Europe. This software is the latest addition to...